Avid Bioservices Inc (CDMO)

[Protector]

PPHM's Cotara has that too, even more then 10 year survival and many other long survivors considering the deathly characters of this brain cancer.

Cotara has PIII design approval, Fast Track, orphan drug status in US and Europe and is given an early exit opportunity on intermediate data for its 300 patients clinical trial.

Besides that Cotara is very well tolerated, needs on a single one shot treatment and according to SK (presentation slides) it will be priced very competitive compared to SOC.

NWBO has no fast track, that means (assume they indeed enroll completely in H1/2014 and come up with results mid/end H2/2014) then 2 years on average must be added for FDA approval/refusal. Cotara with the fast track qualifies for the 6 month short procedure and doesn't need to enroll all 300 patients compared to NWBO's 312 patients.

Last but not least with the orphan status of Cotara comes marketing protection in the US and Europe, which NWBO doesn't has!

So in practice this is a race PPHM should win hands down. Let's see how management plays this!